期刊
EUROPEAN UROLOGY OPEN SCIENCE
卷 45, 期 -, 页码 38-40出版社
ELSEVIER
DOI: 10.1016/j.euros.2022.05.015
关键词
Prostate cancer; Abiraterone; Docetaxel; Enzalutamide; Apalutamide; Darolutamide
The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has undergone significant changes. Combinatorial therapy with ADT and docetaxel or an androgen receptor pathway inhibitor has become the standard of care. Scientific evidence supports the optimization and intensification of this treatment strategy.
The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has dramatically evolved. Monotherapy androgen deprivation therapy (ADT) with testosterone suppression alone is no longer the standard of care as multiple global phase 3 trials of different combinatorial strategies have been clinically and statistically successful and the combinations have been incorporated into guidelines on advanced prostate cancer. For appropriate patients, clinicians should consider combining ADT with docetaxel or an androgen receptor pathway inhibitor, or possibly with both. Shared patient-physician decision-making mandates a review of the level 1 evidence supporting the optimization and intensification of combination therapy for patients with mHSPC. Here we discuss the evidence underscoring intensification strategies as the standard of care for low-volume, Patient summary: We discuss treatment strategies for men with metastatic prostate cancer. Combinations of androgen deprivation therapy (ADT) and drugs that inhibit the androgen receptor pathway are superior to ADT alone and prolong survival in (c) 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据